Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07832136) titled 'An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Viridian Therapeutics, Inc.
Condition:
Thyroid Eye Disease
Intervention:
Drug: veligrotrug (LUMVOA™)
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: September 2026
Target Sample Size: 30
Countries of Recruitment:
United States
To know more, visit https://clinicaltria...